Sumida Tomokazu S, Dulberg Shai, Schupp Jonas, Stillwell Helen A, Axisa Pierre-Paul, Comi Michela, Lincoln Matthew, Unterman Avraham, Kaminski Naftali, Madi Asaf, Kuchroo Vijay K, Hafler David A
Departments of Neurology and Immunobiology, Yale School of Medicine, New Haven, CT, USA.
Department of Pathology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
bioRxiv. 2020 Oct 31:2020.10.30.362947. doi: 10.1101/2020.10.30.362947.
While inhibition of T cell co-inhibitory receptors has revolutionized cancer therapy, the mechanisms governing their expression on human T cells have not been elucidated. Type 1 interferon (IFN-I) modulates T cell immunity in viral infection, autoimmunity, and cancer, and may facilitate induction of T cell exhaustion in chronic viral infection . Here we show that IFN-I regulates co-inhibitory receptors expression on human T cells, inducing PD-1/TIM-3/LAG-3 while surprisingly inhibiting TIGIT expression. High-temporal-resolution mRNA profiling of IFN-I responses enabled the construction of dynamic transcriptional regulatory networks uncovering three temporal transcriptional waves. Perturbation of key transcription factors on human primary T cells revealed both canonical and non-canonical IFN-I transcriptional regulators, and identified unique regulators that control expression of co-inhibitory receptors. To provide direct in vivo evidence for the role of IFN-I on co-inhibitory receptors, we then performed single cell RNA-sequencing in subjects infected with SARS-CoV-2, where viral load was strongly associated with T cell IFN-I signatures. We found that the dynamic IFN-I response in vitro closely mirrored T cell features with acute IFN-I linked viral infection, with high LAG3 and decreased TIGIT expression. Finally, our gene regulatory network identified SP140 as a key regulator for differential LAG3 and TIGIT expression. The construction of co-inhibitory regulatory networks induced by IFN-I with identification of unique transcription factors controlling their expression may provide targets for enhancement of immunotherapy in cancer, infectious diseases, and autoimmunity.
虽然抑制T细胞共抑制受体彻底改变了癌症治疗,但人类T细胞上这些受体表达的调控机制尚未阐明。1型干扰素(IFN-I)在病毒感染、自身免疫和癌症中调节T细胞免疫,并可能在慢性病毒感染中促进T细胞耗竭。在这里,我们表明IFN-I调节人类T细胞上共抑制受体的表达,诱导PD-1/TIM-3/LAG-3,同时令人惊讶地抑制TIGIT表达。对IFN-I反应的高时间分辨率mRNA分析能够构建动态转录调控网络,揭示三个时间转录波。对人类原代T细胞上关键转录因子的扰动揭示了经典和非经典的IFN-I转录调节因子,并确定了控制共抑制受体表达的独特调节因子。为了提供IFN-I对共抑制受体作用的直接体内证据,我们随后对感染SARS-CoV-2的受试者进行了单细胞RNA测序,其中病毒载量与T细胞IFN-I特征密切相关。我们发现体外动态IFN-I反应与急性IFN-I相关病毒感染的T细胞特征密切相关,LAG3高表达而TIGIT表达降低。最后,我们的基因调控网络确定SP140是LAG3和TIGIT差异表达的关键调节因子。构建由IFN-I诱导的共抑制调控网络并鉴定控制其表达的独特转录因子,可能为增强癌症、传染病和自身免疫性疾病的免疫治疗提供靶点。